Open AccessThe 'Holy Grail' in Immuno-Oncology: AC BioScience SA is Aiming to Potentiate Anti-PD-1 Therapy Efficacy through Tumor Cell Conditioning Strategy
Author(s) -
Andreas Schläpfer,
Christian Auclair,
Bassam Janji,
Manale Karam,
Muhammad Zaeem Noman
Publication year - 2020
Publication title -
chimia
Language(s) - English
Resource type - Journals
eISSN - 2673-2424
pISSN - 0009-4293
DOI - 10.2533/chimia.2020.771
Subject(s) - medicine , clinical trial , holy grail , oncology , cancer therapy , immune system , tumor cells , clinical oncology , cancer research , cancer , pharmacology , immunology , world wide web , computer science
AC BioScience is a Swiss biotech company based at the EPFL Innovation Park and Biopôle, dedicated to developing groundbreaking therapies to fight a range of cancers and infectious diseases. We are about to start clinical trials with two of four leading-edge cancer drugs mainly focusing on immune-oncology and tumor vascular normalization with multi-billion $ sales potential. Here, we present our strategy and one of our pioneering drug candidates that has already shown exceptional results with tumor cell conditioning to improve the efficacy of immune checkpoint inhibitors.